Zacks Investment Research downgraded Rockwell Medical Inc (NASDAQ:RMTI) to Sell in a report released today.
- Updated: October 15, 2016
Zacks Investment Research has downgraded Rockwell Medical Inc (NASDAQ:RMTI) to Sell in a report released on 10/12/2016.
Previously on Friday August 19, 2016, BTIG Research released a statement about Rockwell Medical Inc (NASDAQ:RMTI) increased the target price from $0.00 to $12.00. At the time, this indicated a possible upside of 0.66%.
Just yesterday Rockwell Medical Inc (NASDAQ:RMTI) traded -3.51% lower at $6.51. Rockwell Medical Inc’s 50-day moving average is $6.81 and its 200-day moving average is $7.80. The last stock price is down -22.45% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 284,999 shares of RMTI traded hands, down from an average trading volume of 285,749
Recent Performance Chart
Rockwell Medical Inc has 52 week low of $5.47 and a 52 week high of $13.10 and has a market capitalization of $0.
General Information About Rockwell Medical Inc (NASDAQ:RMTI)
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.